PrimaryTumorSidednessasPrognosticandPredictive BiomarkerinMetastaticColorectalCancer FurtherValidationofaPotentiallyPractice-ChangingVariable
http://jamanetwork.com/journals/jamaoncology/article-abstract/2565702
Postagens
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607427 Strosberg J 1 , El-Haddad G 1 , Wolin E 1 , Hendifar A 1 , Yao J 1 , Chasen B 1 , Mittra E 1 , Kunz PL 1 , Kulke MH 1 , Jacene H 1 , Bushnell D 1 , O'Dorisio TM 1 , Baum RP 1 , Kulkarni HR 1 , Caplin M 1 , Lebtahi R 1 , Hobday T 1 , Delpassand E 1 , Van Cutsem E 1 , Benson A 1 , Srirajaskanthan R 1 , Pavel M 1 , Mora J 1 , Berlin J 1 , Grande E 1 , Reed N 1 , Seregni E 1 , Öberg K 1 , Lopera Sierra M 1 , Santoro P 1 , Thevenet T 1 , Erion JL 1 , Ruszniewski P 1 , Kwekkeboom D 1 , Krenning E 1 ; NETTER-1 Trial Investigators . Author information Abstract Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatost
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
http://ascopubs.org/doi/pdf/10.1200/JCO.2016.68.6907
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jnci/108/11/10.1093_jnci_djw149/3/djw149.pdf?Expires=1486498806&Signature=D5t4iVASzP~WMyxz7aNWJyzj8mdUsyNk~WR~kbEnGBk~U4fMfQJacO33ZfqFtuteOppZiOPHvZtqD6v0G7Kg7TbyHi0bQ2c0OjW5wlmqMHFmxRVZDwUn7yw2utWjcXrtrzL2KoWTevmBy2-hNqHWswqgVitnyvAjQeIlWXs8fYsALGdUjCywmIFMPRU4E4o6BxCAb4mBi87rFuak9fgMFuCOXV7ojVOaZfBK41jOF33IA~oZh0-V8rK9HE2HUljCn3zPzubWJToTu26hvyGaCZKSkebL6eOZneUTbwRooUenYVgqt786G6xZmt3Rz5aODbGa2Bc6AikDtKGiagooKg__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer
https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jnci/108/12/10.1093_jnci_djw171/2/djw171.pdf?Expires=1486498358&Signature=LXUmUEpK11Iswho097-cTnXRGB9N0pWxmoJ22~o72FFKF9AntRurRVGzTKSPsIbLDeU~RBGpqmLuZerXZJ4efVXiPyYw~0QeATATBOFCgDc4jx0N98LATlAWVo5FLGYNU3e1UW3KgKl7FKdtl70zZ3SNjEe2ypWQbkH8t80hUJK-KyvZyGp90C23Joxl5JYZJedhXRVm1eT3jKbqzELWfvDHu4z4YOk2glZWQHxw3tjK89z5kJS4GYYZypj9GN2l33q4wAwsBoLKfS6rZjCEglRRkdOOb-YV37pDPClIbZ1rrjKEVW2H3VSORF25xFGmkisePmgwcwTB3EV29L7ifg__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
Grilled, Barbecued, and Smoked Meat Intake and Survival Following Breast Cancer
https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jnci/109/6/10.1093_jnci_djw299/2/djw299.pdf?Expires=1486497250&Signature=gpxEfP3GOAlncm7wtxErvscPPkaKVArx7Ko8kVD0UiEoFFFuvwwxRBzF2OWLTBMchhtD9yLJCoAszRnRKhFn6zhWFxnItT0U3T5-Tb8OFvTZ4j4F3qKpJuZLNJ~Y2wQR7MHhbR0M5g8fKzPwjGV61pl85YMzJItfNNhbBjUPT5m~OGxdSfzcKUf5HPYP1HgbNmNNrIVY5uDiR8kjHlSbn~AcPCCmoLsk8Dgnmm-9r2OicxEw9-oYFAr3UrXCocXeVtmwM7NKHMHEsKJPl4gdJ908ivtXm5DejwmSwcQe~73ilDspJYItB5aIKWTxu4ClxC6qAdPikHyDQ67rmFHzCQ__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial
https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jnci/109/2/10.1093_jnci_djw207/2/djw207.pdf?Expires=1486496643&Signature=RwwLT2ZQYIXoxuAk62mMqURuG4locZLTKOfsg5obTqlchZDb7dDwyzM7n6IdnuLSBLX01SkT9RhpNt6F-iqfpu1j64lLnZ44XpRUWFPTbn9IWuT2Fdp2UgYHqlMAqz~5NFaNRHjuylPuBU17O7~6l-2cU9TU5qEMW-iaZ8y9D1Q0V5uAqCY4mz8mxhiBz-xxLO8lyi5l33pNuXBUSz4xS6ILXHXCPIYT2mPDPzv5CfOGSwznH9sY80b-cFUTrmvIhfa8d8ALTD6BfqWDeX63DJTHVB-8-atNN6iNZBTNd0qT192u7fXTJXg~lDKhdrrC16Ry4IOtYnn9u9r9AxpMnA__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jnci/109/1/10.1093_jnci_djw177/3/djw177.pdf?Expires=1486496011&Signature=feTjPJMiN5ZlXIKG350Kk7boM0~ExHuS~KypSW4NrbyEawIV72k5-WhCvchUs9sYZ82zIHGkr4wcjiE5HV~E9LIcGcg8UqULSv0ZJ5Y7i6qh54khvIyY2vyFuc5AZwu3~Zr~rS1DhKXIVaLbiKszLlJcA2iOS3YfgAO3hYOV6a6M3LgW-lpsRfonNvBb7552EZJY4tnbsYi3eMUDzeBbE6UygDmslM5a-7zYzXRwrJxO2bmYLptfmRPMePlQGNfQT2~FN0SEFKxbTNDPVwe7gOHCuqqirtk1GiwWHPR~tQVi648LiUxML16RnnsBLWD0tSFZp51V5-bsgazycn~Rcw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jnci/109/6/10.1093_jnci_djw279/2/djw279.pdf?Expires=1486493864&Signature=GNxhmhwagsVrnmANJ~N~SUOuD1TQLlCR6M6QBpqMGmJJkD3P7jxp0xFZRdPWLiz15i3M6TLf8V0JAPBUwhSkTboLQK6vmYCiTED7aWBTUFgTJ6WnPn7k0Ko6sAQUwmJGMh8OinNxou2ikDlDrVnqwrMrb7V-Fcr19E0sN4XriYsd1pL29zIuc-pM8GHU5xgeN-YMe0SRnsMpcWvqb3B2EUN4giWKBZWR~GxOmlQUDv-VZAyWdWGCVFMKT5bjZqMVvpvtzQKDZHdgv1Fng0LdQneAyIey5Ugi6F1~xLAK5J7Wdkb6G8pynKlt46Rp20CKqQifc0od-UdCEzL0jsgy~A__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
(oncotype)21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jnci/109/4/10.1093_jnci_djw259/2/djw259.pdf?Expires=1486400420&Signature=BCjr8VtORdUdCiOXsayq5g1Ms6fKr2M23Rj7vXVP5K8I1QT9IOaEzm9UOHlO7laMi6qb04d0x0u1t~yVkJBeHhbmPddhdCwkjYzcPumPgAZNSzJ~eR3FBxHXVGsT0p9UaSIWQsnpUBC4HLAX4TSKWMtEfs5PiJqHnhimhBh6mRVUJCGbDCQFWKRyDRaeQyNuK2iwDYsyLOi3besS59fTGP~2xadvXB3AyOweL-GjhT65OG59w7P--LOI9tjdPNgTqBIRnGKLmzkWy27aRD7XCaQ8mBEQDPP8tRM3VE53iLtdZXATcptNCJHS7sTap3aGNaPGXqDilifeN5hNB1knhA__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
